Cytosorbents (CTSO) Common Equity (2016 - 2025)
Historic Common Equity for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $9.0 million.
- Cytosorbents' Common Equity fell 3138.01% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year decrease of 3138.01%. This contributed to the annual value of $11.1 million for FY2024, which is 5269.84% down from last year.
- Cytosorbents' Common Equity amounted to $9.0 million in Q3 2025, which was down 3138.01% from $11.6 million recorded in Q2 2025.
- Over the past 5 years, Cytosorbents' Common Equity peaked at $77.3 million during Q1 2021, and registered a low of $9.0 million during Q3 2025.
- For the 5-year period, Cytosorbents' Common Equity averaged around $34.5 million, with its median value being $24.5 million (2023).
- In the last 5 years, Cytosorbents' Common Equity soared by 26248.75% in 2021 and then crashed by 5269.84% in 2024.
- Over the past 5 years, Cytosorbents' Common Equity (Quarter) stood at $62.6 million in 2021, then crashed by 43.47% to $35.4 million in 2022, then crashed by 33.62% to $23.5 million in 2023, then crashed by 52.7% to $11.1 million in 2024, then fell by 18.79% to $9.0 million in 2025.
- Its last three reported values are $9.0 million in Q3 2025, $11.6 million for Q2 2025, and $14.5 million during Q1 2025.